IP Library Granted Patent US 8,895,264
Granted Patent B2
US 8,895,264 · App. 13/660,843 · Granted Nov 25, 2014

Methods and compositions for modification of the

Inventors: Gregory J. Cost (Berkeley, CA); Michael C. Holmes (Oakland, CA); Noriyuki Kasahara (Oakland, CA); Josee Laganiere (El Cerrito, CA); Jeffrey C. Miller (San Leandro, CA); David Paschon (Oakland, CA); Edward J. Rebar (San Francisco, CA); Fyodor Urnov (Richmond, CA); Lei Zhang (Davis, CA)
Assignees: Sangamo BioSciences, Inc.; The Regents of the University of California
C12N15/85C12N9/1077C12N15/907C12N9/96C12Y204/02008
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,895,264
App. No.
13/660,843
Granted
Nov 25, 2014
Kind
B2
Abstract

Nucleases and methods of using these nucleases for modification of an HPRT locus and for increasing the frequency of gene modification at a targeted locus and clones and for generating animals.

Claims (20)

1. A non-naturally occurring fusion protein comprising a transcription activator like effector domain DNA binding protein (TALE) that binds to a target site in an endogenous hypoxanthine guanine phosphoribosyltransferase (HPRT) gene comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs:69-78 and a nuclease cleavage domain, wherein the TALE domain comprises a repeat variable diresidue (RVD) sequence in the order presented and selected from a single row of Table 4.

2. A polynucleotide encoding the non-naturally occurring fusion proteins of claim 1 .

3. An isolated cell comprising the fusion proteins of claim 1 .

4. An isolated cell comprising the polynucleotides of claim 2 .

5. The isolated cell of claim 3 , wherein the cell is selected from the group consisting of a T-cell, a B-cell or a stem cell.

6. The isolated cell of claim 5 , wherein the stem cell is selected from the group consisting of an embryonic stem cell (ESC), an induced pluripotent stem cell (iPSC), a CD34+ hematopoietic stem cell and a hepatic stem cell.

7. The isolated cell of claim 4 , wherein the cell is selected from the group consisting of a T-cell, a B-cell, or a stem cell.

8. The isolated cell of claim 7 , wherein the stem cell is selected from the group consisting of an embryonic stem cell (ESC), an induced pluripotent stem cell (iPSC), a CD34+ hematopoietic stem cell, and a hepatic stem cell.

9. A kit comprising the fusion protein of claim 1 .

10. A kit comprising the polynucleotide of claim 2 .

11. A method of cleaving an endogenous HPRT gene in an isolated cell, the method comprising: transforming or transfecting said isolated cell comprising said HRPT gene with the polynucleotide of claim 2 , culturing said transformed or transfected isolated cell under conditions such that said fusion proteins is expressed and the HPRT gene is cleaved.

12. The method of claim 11 , wherein the cell is selected from the group consisting of a T-cell, a B-cell or a stem cell.

13. The method of claim 12 , wherein the stem cell is selected from the group consisting of an embryonic stem cell (ESC), an induced pluripotent stem cell (iPSC), a CD34+ hematopoietic stem cell, and a hepatic stem cell.

14. A method of enriching for cells modified by a nuclease at an endogenous HPRT locus, the method comprising:

cleaving said endogenous HPRT gene in said isolated cell according to the method of claim 11 ;

introducing into the cell, said polynucleotide encoding said fusion protein for modification of a second locus of the endogenous HPRT gene;

subjecting the cells to selection with 6-thioguanine, thereby enriching the cells for those in which the endogenous locus has been modified.

15. The method of claim 14 , wherein the endogenous locus is inactivated.

16. The method of claim 14 , wherein the isolated cell is selected from the group consisting of a T-cell, a B-cell or a stem cell.

17. The method of claim 16 , wherein the stem cell is selected from the group consisting of an embryonic stem cell (ESC), an induced pluripotent stem cell (iPSC), a CD34+ hematopoietic stem cell and a hepatic stem cell.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 10, 2014
From: KASAHARA, NORIYUKI
To: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
Reel/Frame 033929/0657 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 24, 2014
From: COST, GREGORY J.; HOLMES, MICHAEL C.; LAGANIERE, JOSEE; MILLER, JEFFREY C.; PASCHON, DAVID; REBAR, EDWARD J.; URNOV, FYODOR; ZHANG, LEI
To: SANGAMO BIOSCIENCES, INC.
Reel/Frame 033387/0866 →
Continuity (3)
Provisional Application 61552309 · Oct 27, 2011
Provisional Application 61556691 · Nov 7, 2011
Related Publication 20130122591A1 · May 16, 2013